Edgar Filing: VERTEX PHARMACEUTICALS INC / MA - Form 8-K

VERTEX PHARMACEUTICALS INC / MA Form 8-K February 03, 2004

QuickLinks -- Click here to rapidly navigate through this document

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 3, 2004

VERTEX PHARMACEUTICALS INCORPORATED

(Exact name of registrant as specified in its charter)

MASSACHUSETTS

(State or other jurisdiction of incorporation)

000-19319

19

04-3039129 (IRS Employer Identification No.)

(Commission File Number)
130 Waverly Street

Cambridge, Massachusetts 02139

(Address of principal executive offices) (Zip Code)

(617) 444-6100

Registrant's telephone number, including area code:

Item 5. Other Events.

On February 3, 2004, Vertex Pharmaceuticals Incorporated issued a press release to report on an amendment to its collaboration agreement with Novartis Pharma AG directed at targets in the protein kinase gene family. A copy of this press release is attached to this Current Report on Form 8-K as Exhibit 99.1.

Item 9. Regulation FD.

On February 3, 2004, Vertex Pharmaceuticals Incorporated issued a press release to provide its full year 2004 financial guidance. A copy of this press release is attached to this Current Report on Form 8-K as Exhibit 99.2.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Edgar Filing: VERTEX PHARMACEUTICALS INC / MA - Form 8-K

VERTEX PHARMACEUTICALS INCORPORATED

(Registrant)

Date: February 3, 2004 /s/ IAN F. SMITH

Ian F. Smith

Senior Vice President and Chief Financial Officer

EXHIBIT INDEX

The following exhibits are filed as part of this current report on Form 8-K:

Exhibit No.	Description
99.1	Press Release of Vertex Pharmaceuticals Incorporated dated February 3, 2004 entitled "Vertex and Novartis Amend Drug Discovery and Development Collaboration."
99.2	Press Release of Vertex Pharmaceuticals Incorporated dated February 3, 2004 entitled "Vertex Pharmaceuticals to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference."

QuickLinks

Item 5. Other Events.
Item 9. Regulation FD.
SIGNATURES
EXHIBIT INDEX